| External factors: | PD-0332991 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Melanoma |
| Experiment: | SA-β-gal activity assay |
| Description: | To establish senescence, presenescent MEFs (passage 4/p4) were treated with PD-0332991 (4 mmol/L for 8 days),Herein, these treated fibroblast populations are referred to as CDK4/6i.Next, we measured SA-β-gal positivity in these cells, revealing that 74% CDK4/6i treated cells were SA-β-gal positive. |
| Target gene: | MDM2//P53//P21/WAF1 |
| R-EF-Target gene: | Downregulation//Downregulation//Upregulation |
| Official symbol(s): | MDM2//P53//P21/WAF1 |
| Target gene experiment: | Western blot |
| Target gene description: | We found that prolonged PD-0332991 treatment promoted a reduction in Mdm2 and p53 protein levels. However, unlike what is observed in liposarcomas, p21Cip1/Waf1 protein levels were elevated in CDK4/6i MEFs in comparison to p4 cells. |
| Regulatory pathway: | NF-κB |
| R-EF-Pathway: | Activation |
| Official symbol(s): | NFKB1 |
| Pathway experiment: | Western blot |
| Pathway description: | In contrast, activating phosphorylation of the NF-kB subunit, p65, was elevated in CDK4/6i, UV, and MMC fibroblasts when compared with control. |
Annotation: